Fosamax - Woe for Merck

Robert Blanchard

Attorney
(866) 735-1102 Ext 545

0 CommentsPrint ArticleSubscribe

My law partner Tim O'Brien made major news today by breaking the Fosamax(R) story to the Wall Street Journal. Of course, they were only interested in how it would affect Merck's stock value. We thought the Wall Street Journal might be more concerned with average citizens when so many moms and pops lost their retirement saving in the scandals involving the major Wall Street brokerage firms. However, if you followed that coverage, you saw their only concern was whether the lawyers were going to make any money out of the losses. Well the people who lost money by these rip-offs, your parents and my parents, never got adequately compensated and the Wall Street Journal didn't care. Business as usual. I don't expect the Journal to be too concerned about the people who do contract death of the jawbone from Fosamax, just whether Merck will lose a penny a share.